The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Frank Jessen focuses on early detection of Alzheimer’s disease (AD) in patients. A particular focus is on clinical and neuropsychological assessment as well as on MR-imaging. Frank Jessen is leading international initiatives to conceptualize the very first signs of AD, such as subjective cognitive decline (SCD). In that context, he is the coordinator of the multisite DELCODE study of the DZNE. Within DELCODE, patients from memory centers are sampled and followed longitudinally with the aim of improving disease course prediction and of developing new disease markers. Together with Michael Wagner, he is heading the clinical and neuropsychological assessment core of the DZNE clinical research section.
He is also strongly engaged in clinical trials in AD and he is the main author of the German guidelines on the diagnosis, treatment and prevention of dementia.
He serves on several boards, including the steering committee of the European Alzheimer’s Disease Consortium (EADC), the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN), the National Institute in Aging-Alzheimer’s Association (NIA-AA) working group for the development of the criteria of Alzheimer’s disease and on the ISTAART advisory council.